Since 1993, the AACR has awarded more than $542 million in grants to fund meritorious research projects across the spectrum of cancer science, including basic, translational, and clinical research. See how the AACR grants program has contributed to the AACR's mission.
The AACR NextGen Grants for Transformative Cancer Research represent the AACR’s flagship funding initiative to stimulate highly innovative research from young investigators. 2017 NextGen grantee, Hani Goodarzi, PhD, shares the impact of this grant on his career and on metastasis research, especially in colorectal cancer.
Kidney cancer is one of the most common cancers in the US. AACR has partnered with Kure It since 2012 to support innovative translational kidney cancer research. Researchers supported by this partnership have made progress against kidney cancer on multiple fronts.
The SU2C-Lustgarten Foundation Pancreatic Cancer Dream Team set out in 2014 to develop immune-based therapeutic strategies for pancreatic ductal adenocarcinoma (PDA). Their efforts were spurred by the underlying hypothesis that the immunosuppressive PDA milieu could be reprogrammed into an immuno-stimulatory one capable of tumor rejection, thus converting PDA into a treatable disease.
When Edna Cukierman, PhD, obtained an independent research position and decided to apply for a cancer research grant, she had one problem: “I didn’t know anything about cancer,” she recalls.
As the coronavirus pandemic continues to ravage the world, conferences and meetings worldwide are being canceled or moved to virtual mode. This loss of in-person interactions has significantly reduced the number of opportunities for researchers to share ideas, present research, learn career advancement skills, and establish connections with peers, colleagues, and potential collaborators.
The AACR-Novocure Tumor Treating Fields Research Grants represent a joint effort to promote and support innovative research focused on Tumor Treating Fields (TTFields), which are intermediate frequency, low intensity, alternating electric fields that disrupt cell division in cancer cells. 2020 grant recipient Carsten Hagemann, PhD, shares his perspectives on the myriad benefits of the grant.
Researchers have been trying to get a better understanding of the biodistribution and durability of the CAR T response once inside the body. Two recent publications in Cancer Research and Clinical Cancer Research have reported on two different kinds of PET imaging techniques to monitor the CAR T cells inside the body.
After undergraduate education at Harvard University, Ravi Majeti earned his MD and PhD at University of California San Francisco. He took an interest in acute myeloid leukemia (AML) in medical school and cared for patients with AML during his residency in internal medicine at Brigham and Women’s Hospital in Boston and Hematology fellowship at Stanford University...
Lung cancer remains the number one cause of cancer-related death. This persistent dismal prognosis has been largely attributed to late-stage diagnosis, when 5-year survival rates are less than 5%. Although the potential of lung cancer screening to reduce lung cancer-related mortality has been demonstrated, there remains a need for more effective and less invasive early detection methods. The AACR-Johnson & Johnson Lung Cancer Innovative Science Grants are fueling...
Despite demonstrated success in many solid tumor types, immune checkpoint blockade (ICB) agents have minimal efficacy in high grade serous ovarian cancer (HGSC). In this study, the authors describe a novel bispecific anti-PD-1/PD-L1 antibody, which showed increased anti-tumor efficacy compared to mono-specific anti-PD-1 or anti-PDL1. The researchers also...